Loading...
Every company here put through the same five checks on growth and cash generation. It describes the industry as it reports today — not which of these to buy.
| LLY | ELI LILLY AND COMPANY | A+ | $1.35T | $1,437.79 | 46.67 | $86.5B | 31.9% |
| JNJ | Johnson & Johnson | A+ | $674.9B | $280.34 | 42.54 | $99.3B | 16.2% |
| ABBV | AbbVie Inc. | B+ | $521.2B | $294.87 | 50.75 | $66B | 15.7% |
| MRK | Merck & Co., Inc. | A | $362.9B | $147.20 | 150.20 | $67.4B | 3.6% |
| NVS | Novartis AG | A | $306B | $160.36 | — | $56.7B | -0.1% |
| AZN | ASTRAZENECA PLC | B+ | $289.7B | $185.49 | 28.36 | $62.4B | 16.4% |
| AMGN | Amgen Inc. | A+ | $253.2B | $468.13 | 27.14 | $38.9B | 24.1% |
| GILD | GILEAD SCIENCES, INC. | A | $210.5B | $169.73 | — | $31B | -12.5% |
| NVO | NOVO NORDISK A/S | C+ | $182.8B | $41.10 | 11.84 | $50.3B | 33.9% |
| PFE | PFIZER INC | C | $167.9B | $29.45 | 42.07 | $63.6B | 6.3% |
| BMY | BRISTOL-MYERS SQUIBB COMPANY | C+ | $128.6B | $62.92 | 13.95 | $50B | 18.5% |
| GSK | GSK plc | A+ | $109.2B | $50.60 | 13.60 | $43.8B | 17.5% |
| SNY | Sanofi | B | $59.1B | $48.43 | 6.81 | $53.5B | 8.7% |
| BIIB | BIOGEN INC. | A | $37.5B | $253.39 | 109.22 | $10.3B | 3.4% |
| GRFS | Grifols SA | A | $6B | $8.86 | 34.48 | $8.4B | 5.3% |
| AMRN | AMARIN CORP PLC\UK | D- | $5B | $11.69 | — | $176.1M | -10.9% |
| OGN | Organon & Co. | D | $3.6B | $13.89 | 18.04 | $6.1B | 3.5% |
| NSRX | Nasus Pharma Ltd | A | $25.7M | $2.85 | — | $1.2B | 0.1% |
| MIRA | MIRA Pharmaceuticals, Inc. | not rated | $12M | $0.62 | — | — | — |
| MDCX | MEDICUS PHARMA LTD. | not rated | $3.4M | $1.79 | — | — | — |
| SCLX | Scilex Holding Company | D | $11.3K | $1.64 | — | $31.6M | -1,469.8% |
Fundamentals from SEC filings, prices from the last market-data pass. Sort by any column; companies with no figure sort last either way.
Sorted by market cap, largest first; click any column to re-sort. Companies with no figure sort last either way, because a missing P/E means unprofitable rather than cheap. Nothing here is a recommendation.